Navigation Links
Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government
Date:7/22/2009

trategic National Stockpile for emergency use in the treatment of inhalation anthrax.

"We are proud of our progress, but it is important to acknowledge that raxibacumab would never have been developed without Project BioShield," said James H. Davis, Ph.D., J.D., Executive Vice President and General Counsel, HGS, and leader of the Company's raxibacumab program with the U.S. Government. "It is widely known that anthrax spores can be aerosolized and turned into a bioterrorist weapon with the potential to cause significant loss of life. With raxibacumab, the United States now has a treatment for inhalation anthrax. It has taken HGS nearly seven years of work, much of it in close partnership with BARDA, to reach the point where we have successfully delivered raxibacumab to the Stockpile and secured this second purchase order. We are delighted to have reached this important milestone, and we look forward to continuing to work closely with BARDA in the interest of our nation's security."

Raxibacumab represents a new way to address the anthrax threat. While antibiotics can kill the anthrax bacteria, they are not effective against the deadly toxins that the bacteria produce. Raxibacumab targets anthrax toxins after they are released by the bacteria into the blood and tissues. In an inhalation anthrax attack, people may not know they are infected with anthrax until the toxins already are circulating in their blood, and it may be too late for antibiotics alone to be effective.

About the Raxibacumab Contract with the U.S. Government

Raxibacumab is being developed under a contract entered into with BARDA in 2006 (Contract Number HHS010020050006C). The order announced today is the second order received under the BARDA contract. HGS recognized $153.8 million in revenue in the first quarter of 2009 from the first delivery of raxibacumab to the Strategic National Stockpile, and wil
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... FRANCISCO , July 29, 2015  AsureQuality ... mobile molecular testing for applications in food and ... hand-held, battery powered real-time PCR device, the Freedom4. ... farm right through to the supermarket shelf for ... This includes involvement in animal disease control and ...
(Date:7/29/2015)... 29, 2015 Research ... addition of the "Global Biosimilars Market, 2015 ... The Global Biosimilars Market, 2015 - 2025, ... growing biosimilars market. With the blockbuster biologics losing ... costs, biosimilars are being viewed as viable substitutes ...
(Date:7/29/2015)... 29, 2015  AmnioChor Inc., an early stage biotech ... pleased to announce that the Musculoskeletal Transplant Foundation of ... invest in their seed round of development of the ... capabilities. AmnioChor,s technology allows cryopreservation of ... stem cells living within those tissues. Amnion is a ...
(Date:7/29/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX) announced today ... released on Thursday, August 13, 2015, before the open ... will host a conference call to discuss the financial ... outlining the financial results and business update will be ... call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference Pfenex ...
Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2
... Sigma-Aldrich(R) (Nasdaq:,SIAL) announced the release of ... Glycoproteomics and Glycomics, a laboratory reference,for life ... http://www.newscom.com/cgi-bin/prnh/20080221/AQTH004A ), The new 2008 Glycobiology ... 1st edition (2004) by including more topics,important ...
... Have Entered into an Agreement Under, Which Genmab Will Acquire ... ... COPENHAGEN, Denmark and REDWOOD CITY, California, February 21, Genmab ... announced today that they have entered into an agreement,under which ...
... Feb. 21 Phlo Corporation,(Pink Sheets: PHLC) (the ... ended December 31, 2007 of $190,072 and $320,256,respectively, ... nine-month,periods ended December 31, 2006 of $3,100 and ... and $315,533 for the three and,nine months ended ...
Cached Biology Technology:New Glycobiology Analysis Manual 2nd Edition Provides Valuable Resource for Novices and Experts in the Field 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 4Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 5Phlo Reports Sharp Revenue Increase 2
(Date:7/21/2015)... YORK , July 21, 2015 ... systems, as seen in the recent U.S. Office ... a solution to the infosec conundrum, but developers ... is stored. To address this dilemma, Biometrics-as-a-Service provider ... its Biometric Tokenization SDK for third party integration. ...
(Date:7/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), a leading developer ... report financial results for the fourth quarter and fiscal ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-455-2260 (conference ...
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... show that in the plant world, bigger isn,t necessarily better. ... that to be a good competitor in the forest, you ... Lonnie Aarssen. "But our research shows it,s virtually the other ... monopolize sunlight, water and other resources, limiting the number of ...
... a "heart healthy" diet and maintaining or increasing participation in ... abilities as we age, according to new research reported today ... (ICAD 2009) in Vienna. "We can,t do anything ... us that there are lifestyle decisions we all can make ...
... University (NTU),s Assistant Professor Li Hoi Yeung, Assistant Professor ... important contribution to the understanding of the process that ... as ,apoptosis, or programmed cell death, is a normal ... million cells a second. According to Professor Li, ...
Cached Biology News:Smaller plants punch above their weight in the forest, say Queen's biologists 2A 'heart healthy' diet and ongoing, moderate physical activity may protect against cognitive decline 2A 'heart healthy' diet and ongoing, moderate physical activity may protect against cognitive decline 3A 'heart healthy' diet and ongoing, moderate physical activity may protect against cognitive decline 4A 'heart healthy' diet and ongoing, moderate physical activity may protect against cognitive decline 5A 'heart healthy' diet and ongoing, moderate physical activity may protect against cognitive decline 6Study by NTU professors provides important insight into apoptosis or programmed cell death 2
... amino acid synthetic peptide whose sequence is derived from bovine ... to carboxy terminus): C - S(338) - K - ... V - A - P - A(348). This ... the polyclonal antibody that reacts with this product and bovine ...
... more than doubles the benefits of high ... analysis cycles of the standard binary system ... tandem mode. Difficult separations are dramatically improved ... heartcut configurations, on-line sample preparation is fully ...
... Components in this kit are prepared with ... Biochains Mitochondria Isolation Kit is designed ... a fast and easy way. One kit ... 100 isolations (enriching mitochondria from 10 ...
... DNA preparations are prepared from customers ... 1mg to multi-gram scales. Small-scale ... preparations are made according to customer ... according to customer needs, and glycerol ...
Biology Products: